Citius Pharmaceuticals, Inc. Deferred Federal Income Tax Expense (Benefit)
Citius Pharmaceuticals, Inc. (CTXR) reported Deferred Federal Income Tax Expense (Benefit) of $576.00 thousand for the 12-month period ending 2023-09-30, per its 10-K filed 2023-12-29.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2023-12-29
- Citius Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was $576.00K, a 0.00% change from fiscal 2022.
- Citius Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was $576.00K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2023-09-30 | $576.00K 10-K · filed 2023-12-29 |
| 2022-09-30 | $576.00K 10-K · filed 2023-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |